Therefore, MAPK pathway inhibitors, such as MEK inhibitors (MEKi), are the typical therapeutic approach when it comes to NRAS‐mutant melanoma (Munoz‐Couselo, Adelantado, Ortiz, Garcia, & Perez‐Garcia, 2017; Santarpia, Lippman, & El‐Naggar, 2012). This evidence concerns the gene MAP2K7 and melanoma.